Navigation Links
Genelabs Technologies Announces Presentation of Data on,Non-Nucleoside HCV Polymerase Inhibitor at 20th International,Conference on Antiviral Research Meeting

REDWOOD CITY, Calif., May 02, 2007 /PRNewswire-FirstCall/ -- Genelabs Technologies, Inc. announced today that a presentation was made today at the 20th International Conference on Antiviral Research being held in Palm Springs, California, on a non-nucleoside hepatitis C virus (HCV) polymerase inhibitor discovered by Genelabs.

The oral presentation was given by Christopher D. Roberts, Ph.D., Director of Medicinal Chemistry at Genelabs, entitled "GL59728: A Potent Allosteric Inhibitor of the HCV NS5b RNA Dependent RNA Polymerase with Excellent Pharmacokinetic Properties."

GL59728 is one of a number of non-nucleoside HCV polymerase inhibitors discovered by Genelabs. In the presentation, Dr. Roberts outlined the lead optimization of certain non-nucleoside HCV polymerase inhibitors through an iterative process involving testing for potency in directly inhibiting HCV NS5b polymerase, inhibiting the replication of an HCV sub-genomic replicon, and pharmacokinetic properties.

The optimized lead that emerged from this chemistry approach, one of several taken by Genelabs, is known as GL59728. The IC50 of GL59728 for inhibition of the HCV NS5b polymerase is 16 nanomolar and the EC50 for inhibition of HCV replicon is 170 nanomolar. Further, GL59728 shows excellent oral bioavailability, exceeding 50% in all four species tested, including higher-order species, low clearance and a half-life consistent with once- or twice-daily dosing. The tissue distribution of GL59728 also appears favorable; since its concentration is enhanced several fold in liver, the site of HCV infection, relative to that obtained in plasma. Importantly, GL59728 was also tested in combination with other classes of HCV antiviral compounds, including a nucleoside chain terminator, a protease inhibitor and interferon alpha, and shown to be additive in activity with each.

In June 2006 Genelabs entered into a license and research co
'"/>




Page: 1 2 3

Related medicine technology :

1. Neose Technologies to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. New Report Looking at Chiral Technologies Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals
3. Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide
4. Palatin Technologies and King Pharmaceuticals Announce Plan To Present Results of Bremelanotide Phase 2b Studies in Men With Erectile Dysfunction
5. Micell Technologies Presents Data on Novel Drug-Eluting Stents
6. OncoGenex Technologies Announces Phase II Data of OGX-011 in Metastatic Breast Cancer at American Association for Cancer Research 2007 Annual Meeting
7. AVAX Technologies Presents Results of Phase I-II M-Vax Trial at Annual Meeting of American Association for Cancer Research
8. Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery of GLP-1 and PYY
9. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
10. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
Post Your Comments:
(Date:7/25/2014)... -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) today ... second quarter 2014 financial results before the NASDAQ Global ... same day, Arena will host a conference call and ... Time). The conference call may be ... for international callers. Please specify to the operator that ...
(Date:7/24/2014)... , July 24, 2014  PTC Therapeutics, Inc. (NASDAQ: ... will host a webcast conference call to report its ... on the company,s business and outlook on Thursday, August ... of the market. The call can ... 935-8152 (international) five minutes prior to the start of ...
(Date:7/24/2014)...  Uroplasty, Inc. (NASDAQ: UPI ), a ... innovative proprietary products to treat voiding dysfunctions, today ... quarter ended June 30, 2014.  Global revenue ... grew 19% to $4.1 million, as compared to ... prior year.  Total revenue for the fiscal first ...
Breaking Medicine Technology:Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11
... PRINCETON, N.J., April 28, 2011 Pharmasset, Inc. (Nasdaq: ... Deutsche Bank Healthcare Conference being held May 2 to 4, ... Bank of America Merrill Lynch Healthcare Conference being held May ... Vegas, NV. Schaefer Price, Pharmasset,s President and Chief Executive Officer, ...
... SILVER SPRING, Md., April 28, 2011 The ... (abiraterone acetate) in combination with prednisone (a steroid) ... cancer who have received prior docetaxel (chemotherapy). ... prostate cancer, the male sex hormone testosterone stimulates ...
Cached Medicine Technology:Pharmasset to Present at Two Upcoming Investor Conferences 2Pharmasset to Present at Two Upcoming Investor Conferences 3FDA Approves Zytiga for Late-Stage Prostate Cancer 2FDA Approves Zytiga for Late-Stage Prostate Cancer 3
(Date:7/28/2014)... CW4K was among those invited to ... and Partnership for a Healthier America (PHA) ... group's DrinkUP effort, which encourages people across ... , The seven organizations added included Brita®, First 5 ... Bottle, Santa Clara Valley Water District and The California ...
(Date:7/28/2014)... TX (PRWEB) July 28, 2014 To ... the Editorial Board of Living with a Disability ... on disabling digestive disorders that include hepatitis, gastrointestinal hemorrhage, ... , The important new article highlights that, in ... those afflicted with hepatitis and other disabling conditions related ...
(Date:7/28/2014)... Building a sense of neighborhood and outdoor fun ... outdoor space is not possible, building a park or ... outside is important. That’s why Old Buckingham Station ... equipment from APCPLAY. , Old Buckingham Station is a ... an historic tourist location of one of the oldest ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Shore Points ... of its investment in Loftware, Inc., through a recapitalization ... Shore Points was the lead investor in Loftware for ... has become the leading international provider of enterprise level ... has been a great investment for us, and we ...
(Date:7/28/2014)... Southlake, Texas (PRWEB) July 28, 2014 ... home care and hospice, PCO, PCA, and PHC in Texas, ... to be a sponsor of the North Texas Chapter of ... Division of the Peruvian American Medical Society. The North Texas ... reach physicians and other professionals interested in improving medical care ...
Breaking Medicine News(10 mins):Health News:CannedWater4Kids (CW4K) Among Those Invited to the White House to Support First Lady Michelle Obama in Welcoming Seven New Organizations to DrinkUP 2Health News:CannedWater4Kids (CW4K) Among Those Invited to the White House to Support First Lady Michelle Obama in Welcoming Seven New Organizations to DrinkUP 3Health News:Living with a Disability Magazine Marks World Hepatitis Day on July 28 with New Article on Disabling Digestive Disorders 2Health News:Living with a Disability Magazine Marks World Hepatitis Day on July 28 with New Article on Disabling Digestive Disorders 3Health News:Playground Creates Outdoor Fun for Community at Old Buckingham Station at Midlothian Village (VA) with APCPLAY© 2Health News:Shore Points Capital Announces Sale of Portfolio Company Loftware 2Health News:Cuidado Casero Sponsors Peruvian American Medical Society (PAMS) Gala 2
... Wednesday launched a major initiative to introduce female condoms ... planning a usage study in six districts. ... Ltd and the National Aids Control Organisation (NACO) began ... at just Rs.3 to NGOs working with female sex ...
... expectancy is projected to increase from the current 64.7 years to ... close to the current US figure of 77.5 years. ... the population division of the UN Department of Economic and Social ... almost quadruple from 6.4 crore in 2005 to 23.9 crore. ...
... into adolescence, a study conducted in Zimbabwe// seems to indicate. ... children infected with HIV at birth die before the age ... noticing older children admitted in HIV clinics. ... at a clinic in Harare, the capital of Zimbabwe and ...
... Food and Drug Administration (FDA) has granted marketing approval to ... Tykerb. ,It has been claimed that Tykerb is ... than the drugs currently available for the purpose. ... in women worldwide. According to statistics, about a million new ...
... the caption 'your smoking kills babies' would be displayed ... people from consuming them, Health Minister Anbumani Ramadoss said ... "cigarette smoking is injurious to health", has lost its ... better. ,All tobacco products like gutkha and ...
... of Health (MoH), United Arab Emirates has revealed 645 cases ... media reported Wednesday. ,"Only a few cases were ... significantly," Ali Shukur, Under-secretary of the Ministry of Health was ... stigma attached to the fatal transmissible disorder was impeding to ...
Cached Medicine News:Health News:India to Market Female Condoms 2
... Katena Products, Inc. is the ... dedicated exclusively to ophthalmic surgical ... to over 7,000 customers in ... a global network of distributors, ...
... Studies have proven that the management of ... blood glucose levels is the most effective way ... comprehensive care aimed at maintaining or improving a ... complex and costly. , ,These have been ...
... intended for detecting trends and tracking patterns ... and older) and children/adolescents (aged 7 to ... use of the G2 Biographer with their ... supplement, not replace, conventional blood glucose monitoring. ...
... Ex-PRESS is a mini ... simplified,method of filtration surgery for ... to trabeculectomy, the shunt reduces ... aqueous humor from the anterior ...
Medicine Products: